New therapeutic agents for pulmonary vascular disease

Paediatric Respiratory Reviews

Volumn 6, Issue 4, 2005, Pages 285-291

  Howard, Luke S G E ^a   Morrell, Nicholas W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Drugs; Pharmacology; Pulmonary circulation; Pulmonary hypertension

Indexed keywords

ADRENOMEDULLIN; AMBRISENTAN; ARGININE; BERAPROST; BONE MORPHOGENETIC PROTEIN 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ELASTASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN TRANSPORTER; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNINDEXED DRUG; UNIPROST; VARDENAFIL;

CHILD; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; FLUSHING; HEADACHE; HEPATITIS; HUMAN; LIVER DYSFUNCTION; LUNG VASOCONSTRICTION; MANAGED CARE; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY DISEASE; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT;

ADULT; ANTIHYPERTENSIVE AGENTS; ARGININE; CHILD; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; SULFONAMIDES;

EID: 28444433396     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2005.09.006     Document Type: Review

References (50)

1. I.M. Lang D. Bonderman M. Kneussl et al. Paediatric pulmonary vascular disease Paediatr Respir Rev 5 2004 238-248
2. R.M. Tuder C.D. Cool M.W. Geraci et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am J Respir Crit Care Med 159 1999 1925-1932
3. V.V. McLaughlin A. Shillington S. Rich Survival in primary pulmonary hypertension: The impact of epoprostenol therapy Circulation 106 2002 1477-1482
4. V.V. McLaughlin S.P. Gaine R.J. Barst et al. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2003 293-299
5. G. Simonneau R.J. Barst N. Galie et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800-804
6. R.J. Barst L.J. Rubin W.A. Long et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296-302
7. D.B. Badesch V.F. Tapson M.D. McGoon et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 2000 425-434
8. Schermuly RT, Yilmaz H, Ghofrani HA et al. Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. Am J Respir Crit Care Med 2005 (In press).
9. H. Olschewski G. Simonneau N. Galie et al. Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322-329
10. N. Nagaya M. Uematsu Y. Okano et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension J Am Coll Cardiol 34 1999 1188-1192
11. N. Galie M. Humbert J.L. Vachiery et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 39 2002 1496-1502
12. R.J. Barst M. McGoon V. McLaughlin et al. Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 2003 2119-2125
13. A. Giaid M. Yanagisawa D. Langleben et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 1993 1732-1739
14. C. Rubens R. Ewert M. Halank et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension Chest 120 2001 1562-1569
15. A. Benigni G. Remuzzi Endothelin antagonists Lancet 353 1999 133-138
16. S. Iwasaki T. Homma Y. Matsuda et al. Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells J Biol Chem 270 1995 6997-7003
17. N. Davie S.J. Haleen P.D. Upton et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells Am J Respir Crit Care Med 165 2002 398-405
18. S.J. Chen Y.F. Chen Q.C. Meng et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats J Appl Physiol 79 1995 2122-2131
19. N.S. Hill R.R. Warburton L. Pietras et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats J Appl Physiol 83 1997 1209-1215
20. R.N. Channick G. Simonneau O. Sitbon et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study Lancet 358 2001 1119-1123
21. R.J. Barst D. Langleben A. Frost et al. Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 441-447
22. D. Langleben T. Brock R. Dixon et al. STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials J Cardiovasc Pharmacol 44 2004 S80-S84
23. D. Langleben A.M. Hirsch E. Shalit et al. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: A 1-year follow-up study Chest 126 2004 1377-1381
24. A. Sebkhi J.W. Strange S.C. Phillips et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension Circulation 107 2003 3230-3235
25. R.T. Schermuly K.P. Kreisselmeier H.A. Ghofrani et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats Am J Respir Crit Care Med 169 2004 39-45
26. E. Michelakis W. Tymchak D. Lien et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide Circulation 105 2002 2398-2403
27. B.K. Sastry C. Narasimhan N.K. Reddy et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study J Am Coll Cardiol 43 2004 1149-1153
28. M.R. Wilkins G.A. Paul J.W. Strange et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study Am J Respir Crit Care Med 171 2005 1292-1297
29. H.A. Ghofrani R. Voswinckel F. Reichenberger et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study J Am Coll Cardiol 44 2004 1488-1496
30. A. Kleinsasser A. Loeckinger C. Hoermann et al. Sildenafil modulates hemodynamics and pulmonary gas exchange Am J Respir Crit Care Med 163 2001 339-343
31. K.A. Fagan B.W. Fouty R.C. Tyler et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia J Clin Invest 103 1999 291-299
32. R.N. Channick J.W. Newhart F.W. Johnson et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests Chest 109 1996 1545-1549
33. S. Mehta D.J. Stewart D. Langleben et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension Circulation 92 1995 1539-1545
34. N. Nagaya M. Uematsu H. Oya et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension Am J Respir Crit Care Med 163 2001 887-891
35. C. Moinard L. Cynober J.P. de Bandt Polyamines: Metabolism and implications in human diseases Clin Nutr 24 2005 184-197
36. R. Feil S. Feil F. Hofmann A heretical view on the role of NO and cGMP in vascular proliferative diseases Trends Mol Med 11 2005 71-75
37. L. Stiebellehner V. Petkov K. Vonbank et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension Chest 123 2003 1293-1295
38. M. Humbert R.J. Barst I.M. Robbins et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 2004 353-359
39. J.D. Roberts Jr. J.R. Fineman F.C. Morin III et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group N Engl J Med 336 1997 605-610
40. J. Sandoval O. Bauerle A. Gomez et al. Primary pulmonary hypertension in children: Clinical characterization and survival J Am Coll Cardiol 25 1995 466-474
41. R.J. Barst G. Maislin A.P. Fishman Vasodilator therapy for primary pulmonary hypertension in children Circulation 99 1999 1197-1208
42. R.J. Barst D. Ivy J. Dingemanse et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension Clin Pharmacol Ther 73 2003 372-382
43. Humpl T, Reyes JT, Holtby H et al. Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension. Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study. Circulation 2005 (In press).
44. V. Petkov W. Mosgoeller R. Ziesche et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J Clin Invest 111 2003 1339-1346
45. N. Nagaya K. Kangawa Adrenomedullin in the treatment of pulmonary hypertension Peptides 25 2004 2013-2018
46. Y.D. Zhao D.W. Courtman Y. Deng et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: Efficacy of combined cell and eNOS gene therapy in established disease Circ Res 96 2005 442-450
47. S. Eddahibi M. Humbert E. Fadel et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension J Clin Invest 108 2001 1141-1150
48. C. Guignabert B. Raffestin R. Benferhat et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats Circulation 111 2005 2812-2819
49. P.G. Phillips L. Long M.R. Wilkins et al. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling Am J Physiol Lung Cell Mol Physiol 288 2005 L103-L115
50. K.N. Cowan A. Heilbut T. Humpl et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor Nat Med 6 2000 698-702